Chun-Ming Lin

Title: The Innovative Contributions of Chun-Ming Lin

Introduction

Chun-Ming Lin is a prominent inventor based in Taipei, Taiwan. He has made significant strides in the field of biotechnology, particularly in the development of novel therapeutic agents. His work focuses on addressing challenges in disease treatment through innovative solutions.

Latest Patents

Chun-Ming Lin holds a patent for a bispecific T cell engager and its uses. This novel fusion protein aims to overcome the current difficulties associated with the application of monoclonal antibodies in disease treatment. It is particularly relevant in fields requiring antibody-dependent cellular cytotoxicity (ADCC), such as the depletion of tumor cells, virally-infected cells, or immune-modulating cells. One example of this fusion protein includes an extracellular domain of a high-affinity variant of human CD16A fused to an anti-CD3 antibody or its antigen-binding fragment, which specifically binds to an epitope on human CD3 or a fragment thereof.

Career Highlights

Chun-Ming Lin is currently associated with Manysmart Therapeutics, Inc., where he continues to contribute to groundbreaking research and development in the biotechnology sector. His innovative approach and dedication to improving therapeutic options have positioned him as a key figure in his field.

Collaborations

Chun-Ming Lin collaborates with talented individuals such as Hsin-Yi Huang and Cheng Hao Liao. These partnerships enhance the research and development efforts at Manysmart Therapeutics, Inc., fostering an environment of innovation and creativity.

Conclusion

Chun-Ming Lin's contributions to biotechnology, particularly through his patented bispecific T cell engager, highlight his commitment to advancing medical treatments. His work not only addresses current challenges but also paves the way for future innovations in the field.